Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Marco TURATTI"'
Autor:
Alberto Gajofatto, Nicolò Cardobi, Francesca Gobbin, Massimiliano Calabrese, Marco Turatti, Maria Donata Benedetti
Publikováno v:
BMC Neurology, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background Nabiximols (Sativex®) is a cannabinoid approved for multiple sclerosis (MS)-related spasticity. Its mechanism of action is partially understood, and efficacy is variable. Objective To conduct an exploratory analysis of brain netw
Externí odkaz:
https://doaj.org/article/1ddb7b989ded4cc9ad61d42fa62670f5
Autor:
Sonia Di Tella, Antonio Marangi, Alessia d’Arma, Laura Mendozzi, Marco Turatti, Milena Sant, Loredana La Mantia, Roberto Lillini, Marco Rovaris, Maria Donata Benedetti, Domenico Caputo
Publikováno v:
Neurological Sciences. 42:5157-5163
The risk of malignancy associated with sequential disease-modifying therapies (DMTs) for patients with multiple sclerosis (MS) is uncertain. The aim of this study was to analyze the risk of cancer in patients with MS treated with azathioprine (AZA) a
Autor:
Marco Turatti, Simone Campagnari, Riccardo Saccà, Cristiano Chiamulera, Federica Armani, Stefano Tamburin, Denise Dal Lago
Publikováno v:
Psychopharmacology
Background Cue-reactivity is the array of responses that smokers exhibit when exposed to conditioned and contextual stimuli previously associated to substance use. The difficulty to experimentally recreate the complexity of smokers’ spatial experie
Autor:
Silvia Bozzetti, Gaetano Cantalupo, Giampietro Zanette, Giuseppina Vitale, Marco Turatti, Romana Hoeftberger, Francesca Rossi, Carmela Zuco, Giorgia Teresa Maniscalco, Fabio Marchioretto, Eugen Trinka, Luca Di Tizio, Salvatore Monaco, Sergio Ferrari, Tiziano Zanoni, Sara Mariotto, Fabio Soldani, Morena Cadaldini, Fabio Rossini, Rachele Delogu
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 91:1145-1153
ObjectiveTo analyse autoantibody status in a well-defined European multicentre cohort of patients with epilepsy of unknown aetiology and to validate the recently proposed Antibody Prevalence in Epilepsy (APE2) and Response to ImmunoTherapy in Epileps
Autor:
Giulia Rossetti, Elisa Orlandi, Marco Turatti, Macarena Gomez Lira, Massimiliano Calabrese, Mattia Zanoni, Alberto Gajofatto
Background Circulating microRNAs have emerged as novel multiple sclerosis (MS) biomarkers. Aims To assess the association between candidate miR expression in serum samples of patients with MS and the disease course. Methods Serum levels of ten microR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79b538769d6691560f544e79e7fc4d2c
http://hdl.handle.net/11562/1018643
http://hdl.handle.net/11562/1018643
Autor:
Marco Zoccarato, Marco Turatti, Diana Ferraro, Luigi Zuliani, Francesca Rossi, Riccardo Orlandi, Chiara Rosa Mancinelli, Alberto Gajofatto, Francesca Gobbin, Sara Mariotto
Publikováno v:
Journal of the Neurological Sciences. 429:118108
Autor:
Nicola De Rossi, Maria Donata Benedetti, Marco Zoccarato, Antonino Pavone, Marco Turatti, Luigi Zuliani, Luisa Grazian, Markus Reindl, Daniela Alberti, GianPietro Sechi, Alessia Farinazzo, Roberto Bombardi, Massimiliano Calabrese, Elia Sechi, Luciano Deotto, Sara Mariotto, Sergio Ferrari, Alberto Polo, Kathrin Schanda, Raffaella Tanel, Morena Cadaldini, Rachele Delogu, Ruggero Capra, Daniele Urso, Chiara Rosa Mancinelli, Gaetano Cantalupo, Alberto Gajofatto, Francesco Janes, Maria Rachele Bianchi, Adriana Bonora, Salvatore Monaco
Publikováno v:
Journal of Neurology
Anti-myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) recently emerged as a potential biomarker in patients with inflammatory demyelinating diseases of the central nervous system. We here compare the clinical and laboratory findings observed i
Autor:
Maria Donata Benedetti, Maurizio Pea, Stelio Mocella, Alberto Gajofatto, Marco Turatti, Antonio Marangi, Francesca Gobbin, Silvia Bozzetti
Publikováno v:
Multiple Sclerosis and Related Disorders. 23:24-26
Fingolimod is a commonly used treatment for highly active relapsing-remitting multiple sclerosis (MS). We describe the case of a 50-year old man on fingolimod since 2011 who presented, in April 2017, with a voluminous swelling of the left tonsil. A l
Autor:
Marco Turatti, Fabio Benedetti, Cristina Tecchio, Guido Cavaletti, Marco Sorio, Salvatore Monaco, Sergio Ferrari, Laura Bertolasi, Maria Chiara Tozzi, Sara Mariotto
Brentuximab vedotin (BV) is an anti-CD30 antibody acting against CD30+ cancer cells through the release of the conjugated microtubule-disrupting agent monomethyl auristatin E (MMAE). BV is currentl...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d9016ed677a57a8c120ff83ef8b0d76
http://hdl.handle.net/11562/994976
http://hdl.handle.net/11562/994976
Autor:
Alberto Gajofatto, Marco Turatti
Publikováno v:
Drugs of Today. 56:37
Siponimod fumarate (BAF-312) is a synthetic sphingosine 1- phosphate (S1P) receptor modulator, which exerts immunomodulating effects mediated by B- and T-cell sequestration in secondary lymphoid organs. S1P receptor modulators have consistently shown